Shorter blood thinner treatment for left ventricular clot
Part of Heart & circulation clinical trials.
This trial tests if patients with a blood clot in the left ventricle can safely stop blood thinner (Apixaban) after at least 3 months, instead of taking it longer. It may help people with no additional risks avoid extra medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with a left ventricular thrombus (a clot in the main pumping chamber of your heart) less than 12 months ago.
- You are currently taking the blood thinner Apixaban (also known as Eliquis).
- You have been on blood thinner treatment for the clot for at least 3 months.
- Your clot is still there but not moving (laminar/mural), or your heart function is still weak (left ventricular dysfunction).
- You do not have any other reason to stay on blood thinners long-term, like a different clot or heart valve issue.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares the blood thinner apixaban to warfarin for treating blood clots in the main pumping chamber of the heart (left ventricle). The goal is to see which medicine is better at preventing strokes and other complications.
This trial tests whether a newer blood thinner, apixaban, works better than the standard warfarin for treating blood clots in the left ventricle after a heart attack. The goal is to see which medication is safer and more effective at preventing complications.
This trial studies whether a specific blood thinner can better treat a left-side heart clot found soon after a heart attack. It may help prevent the clot from getting worse or causing complications.
This trial tests how to use a blood thinner in people after a recent heart attack who have a clot in the left heart chamber confirmed by heart MRI. It may help lower the risk of the clot causing serious complications, but it also requires careful bleeding-safety screening.
This trial tests whether the blood thinner apixaban can prevent dangerous blood clots from forming in the heart's main pumping chamber after a specific type of heart attack. It is for patients who have severe weakness of the left ventricle and no clot already present.
This trial studies whether taking blood thinners for longer helps people whose heart’s main pumping chamber (the left ventricle) has a blood clot. The goal is to see if it prevents further problems like strokes or clot growth.
Hear when a new Left Ventricular Thrombus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.